New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
08:38 EDTCYTXCytori Therapeutics downgraded to Hold from Buy at Ascendiant
News For CYTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 13, 2015
08:03 EDTCYTXCytori provides twelve month data update on Scleradec-I trial
Subscribe for More Information
April 8, 2015
15:00 EDTCYTXCytori CEO spinning 'fairy-tale story' to support company, TheStreet says
Subscribe for More Information
April 7, 2015
08:02 EDTCYTXCytori Therapeutics granted orphan drug status for cellular therpeutic in EU
Cytori Therapeutics announced that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, has designated Cytori’s ECCS-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma. This designation marks the first autologous adipose derived cell therapy for scleroderma granted orphan status in the European Union. Cytori is currently working with leading scleroderma centers in France led by the Assistance Publique des Hôpitaux de Marseille to begin a 40 patient EU pivotal trial called SCLERADEC-II. The trial is a follow-up controlled trial to the first SCLERADEC trial published last August. If successful, this trial would potentially lead to EMA approval of Cytori’s lead therapeutic for this indication in the EU, as an ATMP or Advanced Therapy Medicinal Product. Cytori recently received FDA approval for a phase 3 clinical trial with our ECCS-50 therapeutic in 80 patients with scleroderma associated hand dysfunction. This US clinical trial is currently planned to begin enrolling this year and has recently been granted FDA approval to expand the number of centers from 12 to 20 sites. This US clinical data could also be useful to support regulatory approvals and reimbursement in the EU as well as other global markets.
April 6, 2015
14:35 EDTCYTXCytori Therapeutics Chinese FDA approval 'a major win,' says Roth Capital
Subscribe for More Information
12:44 EDTCYTXOn The Fly: Midday Wrap
Subscribe for More Information
11:31 EDTCYTXCytori Therapeutics' Celution receives major win in China, says Roth Capital
Roth Capital said Cytori and partner Lorem Vascular Chinese FDA approval of Celution is a major win. The firm said the approval should move the needle "signficantly" for Celution and views current valuation for Cytori as attractive. Shares are Buy rated with a $6 price target.
09:22 EDTCYTXOn The Fly: Pre-market Movers
HIGHER: Uniqure (QURE), up 44.2% following strategic collaboration with Bristol-Myers (BMY)... Cytori Therapeutics (CYTX), up 22.4% after Lorem Vascular receives regulatory clearance in China... Curis (CRIS), up 8.5% after FDA grants orphan drug designation to CUDC-907 for the treatment of Diffuse Large B-Cell Lymphoma... Capnia (CAPN), up 5.9% after being awarded a $220,000 NIH grant... Tesla (TSLA), up 3.8% after reporting first quarter deliveries up 55% to 10,030 cars... Ariad (ARIA), up 3.4% following approval of Iclusig in Canada... Lumber Liquidators (LL), up 3.1% after being upgraded to Outperform from Market Perform at Raymond James. LOWER: Magnum Hunter (MHR), down 8.9% after being downgraded to Hold from Buy at Wunderlich... Herbalife (HLF), down following CNBC report that federal law enforcement agencies contacted the company regarding its business practices... Qualcomm (QCOM), down 2.2% following a Wall Street Journal report that the Samsung (SSNLF) Galaxy S6 did not have a Qualcomm LTE modem... Skyworks (SWKS), down 2.1% after being downgraded to Equal Weight from Overweight at Stephens.
08:03 EDTCYTXCytori Therapeutics, Lorem Vascular receive regulatory clearance in China
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use